中国中医药信息杂志Issue(3)：39-43,5.DOI:10.3969/j.issn.1005-5304.2015.03.011
丹参川芎嗪注射液治疗冠心病心绞痛系统评价
Systematic Evaluation on Danshen Chuanxiongqin Injection in the Treatment of Angina Pectoris
摘要
Abstract
Objective To systematically evaluate the clinical efficacy and safety of Danshen Chuanxiongqin Injection (DCI) in the treatment of angina pectoris. Methods Randomized controlled trials (RCTs) regarding DCI in the treatment of angina pectoris were searched in CNKI, VIP, Wanfang Database, CBM, PubMed, Embase and Cochrane Library by Feb. 2014. Two researchers independently retrieved the RCTs and extracted the information. The Cochrane risk of bias method was used to assess the quality of the included studies, and a meta-analysis was conducted with Review Manager 5.2 software. Results A total of 12 RCTs with 1145 participants were included. The meta-analysis indicated that the combined use of DCI and conventional treatment with western medicine was more effective in the outcomes of the total clinical effective rate [RR=1.27, 95%CI (1.19,1.35), P<0.000 01], the total effective rate of ECG [RR=1.34, 95%CI (1.23,1.46), P<0.000 01], and decrease of plasma viscosity [MD=-0.15, 95%CI (-0.25,-0.05), P=0.004] and fibrinogen [MD=-0.96, 95%CI (-1.14,-0.78), P<0.000 01]. And there were no adverse drug reaction reports. Conclusion Based on this systematic evaluation, DCI combined with conventional therapy is effective and relatively safe in treating angina pectoris, but it still needs larger samples, multi-center, and high quality RCT to verify.关键词
丹参川芎嗪注射液/冠心病心绞痛/系统评价Key words
Danshen Chuanxiongqin Injection/angina pectoris/systemic evaluation分类
医药卫生引用本文复制引用
吴嘉瑞,张晓朦,张冰,赵梦迪,盛晓光..丹参川芎嗪注射液治疗冠心病心绞痛系统评价[J].中国中医药信息杂志,2015,(3):39-43,5.基金项目
国家科技支撑计划(2006BAI21B11)；北京中医药大学重点学科开放课题(2013-ZDXKKF-19)；北京中医药大学自主选题项目(2014-JYBZZ-XS-078)；北京中医药大学创新团队项目(2011-CXTD-14) （2006BAI21B11）
